Welcome to our dedicated page for Dalrada Financial Corporation news (Ticker: $DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financial Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dalrada Financial Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dalrada Financial Corporation's position in the market.
Dalrada Financial (OTCQB: DFCO) announced that its healthcare subsidiary, Genefic, has acquired IV Services, , a leading pharmaceutical and infusion management company. This acquisition strengthens Genefic’s market position by expanding its sales and operational footprint, increasing top-line revenue, and enhancing patient care capabilities. The acquisition is non-dilutive to shareholders and allows Genefic to enter the $42 billion global infusion pharmacy management market, which is expected to grow to $70 billion by 2030. Genefic gains new regional presence in Louisiana and Mississippi, complementing its existing operations in several other U.S. states.
Dalrada Financial (OTCQB: DFCO) filed a Form 10-Q for Q3 2024, revealing a revenue of $10.3 million, driven primarily by its pharmaceutical subsidiary, Genefic Specialty Pharmacy. Genefic accounted for $8.6 million, an 80% increase from Q3 2023 and a 95.5% rise from the previous quarter. The company also converted $13.3 million of affiliate debt to Series I preferred shares, reducing net losses to $2.9 million, the lowest since 2021. CEO Brian Bonar emphasized ongoing efforts to clear debt and reduce expenditures, with a net equity of $8.8 million. Dalrada anticipates continued growth in Q4 and a year-over-year revenue increase by the end of fiscal 2024.